Neoantigen Discovery for Cancer Immunotherapy — Hands-on

Understand how tumour mutations are translated into candidate neoantigens for vaccines and T cell therapies. This module focuses on conceptual pipelines from variants and expression through HLA binding ideas, clonality and safety considerations, ending in a prioritised neoantigen panel for translational oncology teams.

Neoantigen Discovery for Cancer Immunotherapy

Help Desk · WhatsApp

Session Index

Session 1 — Tumour Antigens & Neoantigen Concepts Session 2 — From Variants & Expression to Candidates Session 3 — Shortlisting: Filters, Ranking & Risk Session 4 — Design Brief: Neoantigen Panel for Therapy

Session 1

Fee: Rs 8800

Tumour Antigens & Neoantigen Concepts

Classes of tumour antigens and where neoantigens fit in

tumour associated versus tumour specific antigens neoantigens from somatic mutations (conceptual) why neoantigens matter for personalised therapies

Tumour mutation landscape in simple language

single nucleotide variants, indels and fusions frameshifts and splice changes as neoantigen sources overview of clonal versus subclonal mutations

Where neoantigen discovery sits in the immunotherapy workflow

NGS and expression data as inputs candidate lists for vaccines and T cell therapies feedback from clinical and experimental readouts

Session 2

Fee: Rs 11800

From Variants & Expression to Candidate Neoantigens

Conceptual variant and transcript inputs for neoantigen pipelines

tumour and normal sequencing overview expressed mutations and fusion transcripts (orientation) copy number and allele fraction as context

Deriving mutant peptide sequences in principle (no code required)

reference versus mutated protein segments frameshift and splice driven new reading frames windowing ideas for potential epitope lengths

HLA binding and presentation likelihood as guiding concepts

role of patient specific HLA types binding affinity and motif alignment narratives processing and stability ideas in simple terms

Session 3

Fee: Rs 14800

Shortlisting: Filters, Ranking & Risk

Evidence dimensions that influence neoantigen priority (conceptual)

binding strength and HLA coverage ideas tumour expression and clonality orientation support from immunopeptidomics where available

Negative filters and safety oriented thinking (conceptual only)

similarity to self and critical tissues autoimmunity and cross reactivity risk ideas simple flags for high caution candidates

Combining scores into pragmatic ranking schemes (no formulas)

tiering candidates as high, medium and exploratory balancing potency, breadth and safety link to onco immunology and biomarker thinking

Session 4

Fee: Rs 18800

Design Brief: Neoantigen Panel for Therapy

Structuring a neoantigen candidate table for project teams

peptide, mutation, gene and transcript annotation HLA restriction, evidence tags and rank notes on safety and experimental status

Building a panel for vaccine or T cell therapy concepts (conceptual)

choosing a balanced set of high value candidates considering manufacturability and formulation ideas aligning with clinical protocol plans at high level

Communicating assumptions, gaps and next steps clearly

slide ready figures and bullet narratives explicit statements of data and model limits handoff to wet lab, clinical and regulatory stakeholders

PDF

Neoantigen Discovery for Cancer Immunotherapy Training | From Tumour Mutations to Neoantigen Panels

Neoantigen Discovery for Cancer Immunotherapy — Hands-on